checkAd
    Startseite > Aktien > Ventyx Biosciences > Nachrichten
    Ventyx Biosciences Aktie
    4,7800
     
    USD
    -0,62 %
    -0,0300 USD
    Letzter Kurs 02:00:00 Nasdaq
    4,7800
     
    USD
    14.800 STK
    Geldkurs 31.05.24
    4,7900
     
    USD
    3.500 STK
    Briefkurs 31.05.24
    ISIN: US92332V1070 · WKN: A3C53F · SYM: VTYX · USA

    Neueste Nachrichten

    Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
    16.05.24 · globenewswire · Ventyx Biosciences
    Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
    16.05.24 · globenewswire · Ventyx Biosciences
    Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
    09.05.24 · globenewswire · Ventyx Biosciences
    Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
    02.05.24 · globenewswire · Ventyx Biosciences
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
    29.04.24 · Business Wire (engl.) · Ventyx Biosciences
    Robbins LLP Urges VTYX Investors with Large Losses to Contact the Firm Before April 30, 2024, for Information About Their Rights
    18.03.24 · Business Wire (engl.) · Ventyx Biosciences
    Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
    14.03.24 · Business Wire (engl.) · Ventyx Biosciences
    Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
    12.03.24 · Business Wire (engl.) · Ventyx Biosciences
    VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
    12.03.24 · Business Wire (engl.) · Ventyx Biosciences
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Investors
    11.03.24 · Business Wire (engl.) · Ventyx Biosciences
    Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
    11.03.24 · globenewswire · Ventyx Biosciences
    The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Investors
    08.03.24 · Business Wire (engl.) · Ventyx Biosciences